MedGenome launches “ONCOTRACK”, the Liquid Biopsy blood test for cancer recurrence detection and monitoring

India: India is likely to have over 1.73 Million new cases of cancer and over 880,000 deaths due to the disease by 2020. Around 70% of all cancer patients approach the doctor when the disease has advanced, and the chances of cure are very low.

To address and better manage the disease, MedGenome – India’s



premier genomics based research and diagnostics company today announced the launch of “ONCOTRACK”.

The liquid biopsy based Oncotrack is a non-invasive screening test that is set to transform the way physicians in India can identify genetic alterations, interpret, assess and treat various forms of cancer.